Spolverato G, Capelli G, Noel F, Steindler M, Gumbs AA. Pan-immune-inflammation in colon cancer: A prognostic biomarker and the role of tumor location in personalized care. World J Gastrointest Surg 2025; 17(4): 101066 [DOI: 10.4240/wjgs.v17.i4.101066]
Corresponding Author of This Article
Andrew Alexander Gumbs, FACS, MD, MSc, Chief, Full Professor, Department of Surgery, Service de Chirurgie Digestive Minimale Invasive, Hôpital Antoine Béclère, Assistance Publique-Hôpitaux de Paris, 157 Rue de la Porte de Trivaux, Clamart 92140, France. aagumbs@gmail.com
Research Domain of This Article
Surgery
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Surg. Apr 27, 2025; 17(4): 101066 Published online Apr 27, 2025. doi: 10.4240/wjgs.v17.i4.101066
Pan-immune-inflammation in colon cancer: A prognostic biomarker and the role of tumor location in personalized care
Gaya Spolverato, Giulia Capelli, Floriane Noel, Michele Steindler, Andrew Alexander Gumbs
Gaya Spolverato, Department of Surgery, University of Padova, Padua 35122, Italy
Giulia Capelli, Department of Surgery, ASST Bergamo Est, Bergamo 24068, Lombardy, Italy
Floriane Noel, Michele Steindler, Department of Research, Sibylone, Paris 75002, France
Andrew Alexander Gumbs, Department of Surgery, University of Magdeburg, Magdeburg 39130, Saxony-Anhalt, Germany
Andrew Alexander Gumbs, Department of Surgery, Service de Chirurgie Digestive Minimale Invasive, Hôpital Antoine Béclère, Assistance Publique-Hôpitaux de Paris, Clamart 92140, France
Author contributions: Spolverato G, Capelli G, Noel F, Steindler M, and Gumbs AA contributed to this paper; Gumbs AA designed the overall concept and outline of the manuscript; Spolverato G contributed to the discussion and design of the manuscript; Noel F and Steindler M drafted the manuscript; Spolverato G and Capelli G contributed to manuscript writing, editing, and review of the literature. All authors have read and approved the final manuscript.
Conflict-of-interest statement: No conflicts of interest to report.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Andrew Alexander Gumbs, FACS, MD, MSc, Chief, Full Professor, Department of Surgery, Service de Chirurgie Digestive Minimale Invasive, Hôpital Antoine Béclère, Assistance Publique-Hôpitaux de Paris, 157 Rue de la Porte de Trivaux, Clamart 92140, France. aagumbs@gmail.com
Received: September 3, 2024 Revised: February 14, 2025 Accepted: February 25, 2025 Published online: April 27, 2025 Processing time: 206 Days and 20.6 Hours
Abstract
Despite advances in surgery, chemotherapy, and radiotherapy, the treatment of colorectal cancer (CRC) requires more personalized approaches based on tumor biology and molecular profiling. While some relevant mutations have been associated with differential response to immunotherapy, such as RAS and BRAF mutations limiting response to anti-epithelial growth factor receptor drugs or microsatellite instability predisposing susceptibility to immune checkpoint inhibitors, the role of inflammation in dictating tumor progression and treatment response is still under investigation. Several inflammatory biomarkers have been identified to guide patient prognosis. These include the neutrophil-lymphocyte ratio, Glasgow prognostic score (GPS) and its modified version, lymphocyte-C-reactive protein ratio, and platelet-lymphocyte ratio. However, these markers are not yet included in the standard clinical management of patients with CRC, and further research is needed to evaluate their efficacy in different patient populations. A recent study by Wang et al, published in the World Journal of Gastroenterology, sheds light on the prognostic significance of pan-immune-inflammation value (PIV) in CRC, particularly concerning primary tumor location. Specifically, the authors found that a high PIV was strongly correlated with worse disease-free survival in patients with left-sided colon cancer, whereas no such association was observed in patients with right-sided colon cancer. Integrating tumor location into the prognostic assessment of CRC may improve our ability to more accurately identify high-risk patients and develop personalized treatment plans that are more likely to improve patient outcomes.
Core Tip: A recent study by Wang et al highlights that a high pan-immune inflammation value is associated with worse disease-free survival in left-sided colon cancer, but not in right-sided colon cancer. This suggests that considering tumor location in colorectal cancer prognosis may help identify high-risk patients and more effectively tailor treatment plans.
